RxDoctor Payments Data

David Rankine, MD

Neurology · Chattanooga, TNNPI 1851349989

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $138,384 of the $166,612 with a category attached, or 83.1%. 21 manufacturers reported payments, led by EMD Serono, Inc. at 58.8% of the total. Reporting peaked in 2024 at $45,224 and has fallen 87.7% since, to $5,578 in 2025. Among neurology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$166,612in general payments, 2019–2025

Across 229 payments — averaging $727.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$98K
  • AbbVie$46K
  • UCB, Inc.$21K
  • Sunovion Pharmaceuticals Inc.$214
  • AstraZeneca$195
  • Argenx US, Inc.$123
  • plus $556 from 15 others

What the payments were for

  • Consulting fees$5,6503%
  • Speaking & faculty fees$138,38483%
  • Travel & lodging$14,4749%
  • Food & beverage$5,0483%
  • Education$1600%
  • Gifts$2,8952%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$166,612 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$59,932
Medicare patients
202
Services billed
353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EmflazaDeflazacort20$351,186
BriviactBrivaracetam36$51,214
UbrelvyUbrogepant18$23,875
Rasagiline Mesylate125$19,687
VimpatLacosamide18$16,136
Nurtec OdtRimegepant Sulfate11$15,045
AptiomEslicarbazepine Acetate12$13,319
Aimovig AutoinjectorErenumab-Aooe14$10,246
Gabapentin231$5,747
Carbidopa-Levodopa ErCarbidopa/Levodopa99$5,054
Lamotrigine ErLamotrigine14$4,536
Entacapone29$2,436
Donepezil Hcl215$2,253
Pentoxifylline64$1,826
Pregabalin37$1,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat$21,101$67,35154 claims
AbbVieUbrelvy$46,373$23,87518 claims
PfizerNurtec Odt$16$15,04511 claims
Sunovion Pharmaceuticals Inc.Aptiom$214$13,31912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 neurology providers in Tennessee.

Other neurology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →